These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21879295)

  • 41. [(11) C]Carbon monoxide in labeling chemistry and positron emission tomography tracer development: scope and limitations.
    Rahman O
    J Labelled Comp Radiopharm; 2015 Mar; 58(3):86-98. PubMed ID: 25689679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5-(2-18F-fluoroethoxy)-L-tryptophan as a substrate of system L transport for tumor imaging by PET.
    Krämer SD; Mu L; Müller A; Keller C; Kuznetsova OF; Schweinsberg C; Franck D; Müller C; Ross TL; Schibli R; Ametamey SM
    J Nucl Med; 2012 Mar; 53(3):434-42. PubMed ID: 22331220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles.
    Peeters SG; Zegers CM; Yaromina A; Van Elmpt W; Dubois L; Lambin P
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):39-57. PubMed ID: 25517080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PET imaging of αvβ3 expression in cancer patients.
    Beer AJ; Schwaiger M
    Methods Mol Biol; 2011; 680():183-200. PubMed ID: 21153382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Positron emission tomography for modeling pathophysiological processes in vivo.
    Hendrikse NH; Luurtsema G; van der Veldt AA; Lubberink M
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):717-25. PubMed ID: 18729023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents.
    McConathy J; Yu W; Jarkas N; Seo W; Schuster DM; Goodman MM
    Med Res Rev; 2012 Jul; 32(4):868-905. PubMed ID: 21793016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of carbon-11 labelled PET tracers-radiochemical and technological challenges in a historic perspective.
    Antoni G
    J Labelled Comp Radiopharm; 2015 Mar; 58(3):65-72. PubMed ID: 25684179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical imaging and treatment of cancer: the use of animal models beyond rodents.
    Axiak-Bechtel SM; Maitz CA; Selting KA; Bryan JN
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):303-16. PubMed ID: 26200223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
    Slobbe P; Poot AJ; Windhorst AD; van Dongen GA
    Drug Discov Today; 2012 Nov; 17(21-22):1175-87. PubMed ID: 22766374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo imaging as a pharmacodynamic marker.
    van der Veldt AA; Lammertsma AA
    Clin Cancer Res; 2014 May; 20(10):2569-77. PubMed ID: 24831279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
    Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
    Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Noninvasive positron emission tomography imaging of cell death using a novel small-molecule probe, (18)F labeled bis(zinc(II)-dipicolylamine) complex.
    Wang H; Tang X; Tang G; Huang T; Liang X; Hu K; Deng H; Yi C; Shi X; Wu K
    Apoptosis; 2013 Aug; 18(8):1017-27. PubMed ID: 23613106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imaging in Central Nervous System Drug Discovery.
    Gunn RN; Rabiner EA
    Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imaging the life and death of tumors in living subjects: Preclinical PET imaging of proliferation and apoptosis.
    Nguyen QD; Aboagye EO
    Integr Biol (Camb); 2010 Oct; 2(10):483-95. PubMed ID: 20737104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical applications of positron emission tomography in sarcoma management.
    Quak E; van de Luijtgaarden AC; de Geus-Oei LF; van der Graaf WT; Oyen WJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):195-204. PubMed ID: 21342039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo evaluation of [18F]FEAnGA-Me: a PET tracer for imaging β-glucuronidase (β-GUS) activity in a tumor/inflammation rodent model.
    Antunes IF; Haisma HJ; Elsinga PH; Sijbesma JW; Waarde Av; Willemsen AT; Dierckx RA; de Vries EF
    Nucl Med Biol; 2012 Aug; 39(6):854-63. PubMed ID: 22445742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases.
    Döbrössy MD; Braun F; Klein S; Garcia J; Langen KJ; Weber WA; Nikkhah G; Meyer PT
    Nucl Med Biol; 2012 Oct; 39(7):1077-80. PubMed ID: 22591915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
    Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
    Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Applications of Small Animal PET.
    Schelhaas S
    Recent Results Cancer Res; 2020; 216():493-507. PubMed ID: 32594396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.